JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo RIUMAComunidades & ColeccionesPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosDepartamentos/InstitutosEditoresEsta colecciónPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosDepartamentos/InstitutosEditores

    Mi cuenta

    AccederRegistro

    Estadísticas

    Ver Estadísticas de uso

    DE INTERÉS

    Datos de investigaciónReglamento de ciencia abierta de la UMAPolítica de RIUMAPolitica de datos de investigación en RIUMAOpen Policy Finder (antes Sherpa-Romeo)Dulcinea
    Preguntas frecuentesManual de usoContacto/Sugerencias
    Ver ítem 
    •   RIUMA Principal
    • Investigación
    • Artículos
    • Ver ítem
    •   RIUMA Principal
    • Investigación
    • Artículos
    • Ver ítem

    A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.

    • Autor
      Bjornsson, Einar S.; Stephens, Camilla; Atallah, Edmond; Robles-Díaz, María MercedesAutoridad Universidad de Málaga; Alvarez-Alvarez, Ismael; Gerbes, Alexander L; Weber, Sabine; Stirnimann, Guido; Kullak-Ublick, Gerd A; Cortez-Pinto, Helena; Grove, Jane I.; Lucena-González, María IsabelAutoridad Universidad de Málaga; Andrade-Bellido, Raúl JesúsAutoridad Universidad de Málaga; Aithal, Guruprasad P.
    • Fecha
      2023
    • Editorial/Editor
      Wiley
    • Palabras clave
      Hígado - Enfermedades; Efectos indeseables de los medicamentos; Vigilancia epidemiológica
    • Resumen
      Background & Aims: No multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported. Methods: Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016–2021. DILI cases or non-DILI acute liver injury controls following causality assessment were enrolled. Results: Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis (n = 42) and viral hepatitis (n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre-existing liver disease. DILI cases and non-DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin-clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug-induced autoimmune-like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver-related death), and another six received liver transplantation. Conclusions: In this first multi-national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI.
    • URI
      https://hdl.handle.net/10630/37972
    • DOI
      https://dx.doi.org/10.1111/liv.15378
    • Compartir
      RefworksMendeley
    Mostrar el registro completo del ítem
    Ficheros
    A new framework for advancing in DILI research. The PRO EURO DILI Registry.pdf (565.4Kb)
    Colecciones
    • Artículos

    Estadísticas

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
     

     

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA